Big Tech Drives Market Higher Amid Key Earnings

Written by Emily J. Thompson, Senior Investment Analyst

Source: CNBC

Updated: 1 hour ago

0mins

JNJ+0.46%

WDC+5.11%

PLTR+2.2%

Should l Buy JNJ?

Source: CNBC

Tech Stocks Surge: Nvidia's shares rose 2% following a multiyear partnership with Meta, which will utilize millions of Nvidia chips for its data center expansion, thereby enhancing its competitive edge in the tech sector.
Oil Price Impact: WTI crude oil prices increased by 3.4% amid concerns over potential hostilities between the U.S. and Iran, raising costs for gasoline, transportation, and goods, which could negatively affect several stocks in the portfolio.
Cybersecurity Concerns: Despite Palo Alto Networks exceeding earnings expectations, its stock fell 7.3% due to ongoing fears that AI could erode its market share, although the CEO argues that increased AI usage will drive demand for security solutions.
Pharmaceutical Breakthrough: Bristol Myers' FDA-approved drug Camzyos has contributed to a 27% stock price increase over three months, but setbacks in trials for its Alzheimer's treatment raise investor caution regarding future performance.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on JNJ

Wall Street analysts forecast JNJ stock price to fall

20 Analyst Rating

13 Buy

7 Hold

0 Sell

Moderate Buy

Current: 243.330

Low

190.00

Averages

218.50

High

240.00

Current: 243.330

Low

190.00

Averages

218.50

High

240.00

RBC Capital

Outperform

maintain

$240 -> $255

2026-02-03

Reason

RBC Capital

Price Target

$240 -> $255

AI Analysis

2026-02-03

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Johnson & Johnson to $255 from $240 and keeps an Outperform rating on the shares. The company is unlikely to undo the key implications of the Daubert ruling, but with that said, the cases may drag on for years as JNJ litigates this case-by-case and year-by-year, and maintains a strong financial position with improving business fundamentals to help mitigate risks, the analyst tells investors in a research note.

BofA

analyst

Neutral

maintain

$221 -> $227

2026-01-30

Reason

BofA

analyst

Price Target

$221 -> $227

2026-01-30

maintain

Neutral

Reason

BofA raised the firm's price target on Johnson & Johnson to $227 from $221 and keeps a Neutral rating on the shares. The firm's raised target reflects a higher blended P/E multiple, which assumes a higher MedTech multiple on higher organic growth and a higher Pharma multiple given a defensive premium. A Daubert ruling in the talc MDL case could be issued in the next one to two months, notes the analyst, who says that although the outcome of any legal case, including any potential settlement or injunction, is "inherently unpredictable," the firm thinks talc risk should be manageable as even a mid-teens billion resolution cost is less than 3% of J&J's market cap.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JNJ

Unlock Now

About JNJ

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Johnson & Johnson Receives FDA Breakthrough Therapy Designation

5 hours agoNASDAQ.COM

Breakthrough Therapy Designation: Johnson & Johnson's subcutaneous Rybrevant Faspro has received Breakthrough Therapy Designation from the FDA for adult patients with advanced head and neck squamous cell carcinoma, marking a significant advancement in cancer treatment.
Clinical Trial Support: This designation is supported by data from the Phase 1b/2 OrigAMI-4 study, where Rybrevant Faspro demonstrated rapid and durable responses in heavily pretreated patients, enhancing its competitive position in the market.
Multiple Indications: Rybrevant Faspro is already approved for various indications in the treatment of non-small cell lung cancer and is being evaluated for use in other solid tumors, including colorectal cancer, showcasing its broad therapeutic potential.
Stock Performance: Although Johnson & Johnson shares closed at $243.33 on Tuesday, down 0.05%, the Breakthrough Therapy Designation may boost market expectations for its future performance and enhance investor confidence.

Johnson & Johnson Invests Over $1 Billion in Pennsylvania

4 hours agoNewsfilter

Massive Investment: Johnson & Johnson has announced an investment of over $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, which is expected to create over 500 biomanufacturing jobs and 4,000 construction jobs, significantly boosting the local economy.
Significant Economic Impact: This investment is part of the company's broader $55 billion commitment to U.S. investments by 2029, aimed at enhancing its manufacturing capacity in the U.S. to meet the needs of patients, thereby increasing the company's competitiveness in the global market.
Innovative Manufacturing Capability: The new facility will utilize cutting-edge cell therapy technologies to support Johnson & Johnson's portfolio of transformational medicines for cancer, immune-mediated, and neurological diseases, further solidifying its leadership in the life sciences sector.
Local Government Support: The Governor of Pennsylvania highlighted that the state's leadership in life sciences and advanced manufacturing has attracted companies like Johnson & Johnson to increase their investments, demonstrating effective execution of the state's economic development plan and strategic investments in key industries.

JOHNSON & JOHNSON INVESTS OVER $1 BILLION TO GROW U.S. PRESENCE WITH NEW CELL THERAPY MANUFACTURING FACILITY IN PENNSYLVANIA

4 hours agomoomoo

Investment Announcement: Johnson & Johnson is expanding its U.S. footprint with a significant investment exceeding $1 billion.
Focus on Cell Therapy: The investment will be directed towards the establishment of a manufacturing facility in Pennsylvania, specifically for next-generation cell therapy.